SOURCE: NI Research

May 08, 2008 12:07 ET

CNS 2008 Disorders/Therapeutics Released by NI Research

CARDIFF, CA--(Marketwire - May 8, 2008) - NI Research announces the publication of CNS 2008: Disorders/Therapeutics. The 2008 edition of this incomparable CNS industry overview incorporates a first-in-class evaluation of Big Pharma licensing skills and styles; Big Pharma Report Card: Business Development.

There has never been a review of the Business Development and Licensing practices of the major pharmaceutical companies in the US and Europe with this level of detail and candor. The companies are evaluated in terms of their culture, style, and 'user-friendliness' from a small partner viewpoint, and they are graded, from A to F. This review has been assembled from interviews with professionals on both sides of the large and small pharma divide, as well as NI Research's evaluations of the licensing performance over time of each company. For small and midsize companies thinking about strategic 'fit,' this information is indispensable. And for Big Pharma Business Development professionals, it offers an opportunity to find out how your organization, attitude, ability to relate, and performance are perceived. We review and grade BD operations for: Abbott Laboratories, Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Elan, Forest Laboratories, GlaxoSmithKline, Johnson & Johnson, Lilly, Lundbeck, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Shire Pharmaceuticals, and Wyeth. This review also overviews changes in the neuro-program licensing environment, including trends in upfront/milestone payments for projects at various stages of development.

The second essential section of CNS 2008 compiles NI Research's comprehensive reviews of all major psychiatric and neurological indications, and the therapeutics programs under development. Addiction Disorders and Bipolar Disorder are included for the first time. All reviews are fully updated and revised as of May 5, 2008. This provides strategic planners and Business Development professionals with a complete review of the neuro and psychopharmaceutical universe of therapies in development, in a single searchable pdf. The disorders reviewed are: Addiction, Alertness/EDS, Alzheimer's, ALS, Anxiety, ADHD, Bipolar Disorder, Depression, Epilepsy, Huntington's, Insomnia, Memory Disorders (MCI/AAMI), MS, Neuropathic Pain, Nociceptive Pain, Parkinson's, Schizophrenia, Spinal Cord Injury, Spinal Muscular Atrophy, Stroke, TBI.

There is no other publication, at any price, that covers these areas with the depth and candor that CNS 2008 Disorders/Therapeutics provides.

364 pages $7500 (early-stage companies are invited to inquire about pricing options)

To download information and order form:

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003, and CNS Disorders/Therapeutics since 2007. NI Research also provides inlicensing consultation and custom research for large and small pharmaceutical firms. NI Research has developed an unmatched information base covering publicly and privately held neuro-oriented companies.

Contact Information